Precision Biosciences (DTIL) Other Gross PP&E Adjustments (2018 - 2026)
Precision Biosciences (DTIL) reported Other Gross PP&E Adjustments of -$5.5 million for Q1 2026, up 19.41% year-over-year from -$4.6 million in Q1 2025, and down 122.47% on a QoQ basis from $24.3 million in Q4 2025.
Precision Biosciences (DTIL) has 9 years of Other Gross PP&E Adjustments data on file, last reported at -$5.5 million in Q1 2026.
- Quarterly Other Gross PP&E Adjustments rose 19.41% year-over-year to -$5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.5 million (up 19.41% YoY) and the FY2025 annual result came in at $24.3 million, up 0.98% from the prior year.
- Other Gross PP&E Adjustments declined to -$5.5 million in Q1 2026 per DTIL's latest filing, from $24.3 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at $31.7 million in Q4 2022 and bottomed at -$8.0 million in Q1 2024.
- The 5-year median for Other Gross PP&E Adjustments is -$3.9 million (2022), against an average of $2.1 million.
- The widest annual swing landed in 2023, when Other Gross PP&E Adjustments jumped 67.28%; it then slumped 587.08% in 2024.
- Tracing DTIL's Other Gross PP&E Adjustments over 5 years: stood at $31.7 million in 2022, then dropped by 25.72% to $23.6 million in 2023, then gained by 2.17% to $24.1 million in 2024, then grew by 0.98% to $24.3 million in 2025, then tumbled by 122.47% to -$5.5 million in 2026.
- Per Business Quant, the three latest DTIL Other Gross PP&E Adjustments figures stand at -$5.5 million (Q1 2026), $24.3 million (Q4 2025), and -$6.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Precision Biosciences | 171.70 Mn | 70.52 Mn | - | -5.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.46 Mn |
| Mar 31, 2026 | -5.46 Mn |
| Dec 31, 2025 | 24.31 Mn |
| Dec 31, 2025 | 24.31 Mn |
| Sep 30, 2025 | -6.14 Mn |
| Sep 30, 2025 | -6.14 Mn |
| Jun 30, 2025 | -6.46 Mn |
| Jun 30, 2025 | -6.46 Mn |
| Mar 31, 2025 | -6.78 Mn |
| Mar 31, 2025 | -6.78 Mn |
| Dec 31, 2024 | 24.08 Mn |
| Dec 31, 2024 | 24.08 Mn |
| Sep 30, 2024 | -7.39 Mn |
| Sep 30, 2024 | -7.39 Mn |
| Jun 30, 2024 | -7.69 Mn |
| Jun 30, 2024 | -7.69 Mn |
| Mar 31, 2024 | -7.98 Mn |
| Mar 31, 2024 | -7.98 Mn |
| Dec 31, 2023 | 23.56 Mn |
| Dec 31, 2023 | 23.56 Mn |
| Sep 30, 2023 | -1.08 Mn |
| Sep 30, 2023 | -1.08 Mn |
| Jun 30, 2023 | -4.72 Mn |
| Jun 30, 2023 | -4.72 Mn |
| Mar 31, 2023 | -2.65 Mn |
| Mar 31, 2023 | -2.65 Mn |
| Dec 31, 2022 | 31.72 Mn |
| Dec 31, 2022 | 31.72 Mn |
| Sep 30, 2022 | -3.29 Mn |
| Sep 30, 2022 | -3.29 Mn |
| Jun 30, 2022 | -3.60 Mn |
| Jun 30, 2022 | -3.60 Mn |
| Mar 31, 2022 | -3.89 Mn |
| Mar 31, 2022 | -3.89 Mn |
| Dec 31, 2021 | 44.89 Mn |
| Dec 31, 2021 | 44.89 Mn |
| Sep 30, 2021 | -5.51 Mn |
| Sep 30, 2021 | -5.51 Mn |
| Jun 30, 2021 | -5.82 Mn |
| Jun 30, 2021 | -5.82 Mn |
| Mar 31, 2021 | -6.12 Mn |
| Mar 31, 2021 | -6.12 Mn |
| Dec 31, 2020 | 47.76 Mn |
| Dec 31, 2020 | 47.76 Mn |
| Sep 30, 2020 | -6.69 Mn |
| Sep 30, 2020 | -6.69 Mn |
| Jun 30, 2020 | -6.50 Mn |
| Jun 30, 2020 | -6.50 Mn |
| Mar 31, 2020 | -6.59 Mn |
| Mar 31, 2020 | -6.59 Mn |
| Dec 31, 2019 | 50.22 Mn |
| Dec 31, 2019 | 50.22 Mn |
| Dec 31, 2018 | 26.63 Mn |
| Dec 31, 2018 | 26.63 Mn |